Transfer Factor in Hodgkin's Disease

Ng, Raymond W. M.; Moran, Cesar; Alexopoulos, Constantinos; Bellingham, A. J.

doi:10.1016/s0140-6736(75)92131-5

Cited by 16 publications

(6 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Apparently normal proportions of E-rosette-forming lymphocytes are not necessary for a normal PHA response, since E-rosetteforming proportions were essentially unchanged after glass wool depletion while PHA responsiveness was enhanced in patients with HD. Similarly, Ng et al found that PHA responsiveness increased without any increase in proportions of E-rosette-forming cells when transfer factor was given to patients with HD (36).…”

Section: Removal Of Glass Wool-adherent Cellsmentioning

confidence: 88%

Studies of Cell Subpopulations Mediating Mitogen Hyporesponsiveness in Patients with Hodgkin's Disease

Sibbitt¹,

Bankhurst²,

Williams³

1978

J. Clin. Invest.

View full text Add to dashboard Cite

A B S T R A C T Hodgkin's disease (HD) is associated with a deficit in T-cell immunity characterized by skin test anergy and decreased lymphocyte responses to phytohemagglutinin (PHA). To investigate this mitogen hyporesponsiveness in HD, we separated peripheral blood mononuclear cells on Ficoll-Hypaque gradients and determined their response to various suboptimal concentrations of PHA. As was expected, patients with HD demonstrated marked mitogen hyporesponsiveness relative to normal controls; however, if the cell suspensions were first passed through glass wool columns to remove adherent cells, the PHA responsiveness of the hyporesponsive HD cells was markedly increased. In contrast, the responsiveness of normal controls was decreased so that the responses of nonadherent normal and HD cells were statistically indistinguishable. Evidently, a glass wool-adherent suppressor cell had been removed from patients with HD, while a glass wool-adherent cell which enhanced mitogenic responses had been removed from normal controls during column passage. Previous to column depletion, patients with HD had decreased proportions of E-rosettes and increased proportions of cells with surface a-fetoprotein; however, the proportion of these cells was not changed after column passage. Significant changes with column depletion of glass wool-adherent cells in HD were recorded in the proportions of monocytes (13.2 vs 5.8%) and lymphocytes with C-3 receptors (12.6 vs. 7.8%). The only significant change in normal controls was a decrease in the proportion of monocytes (10 vs. 1.7%). To determine ifglass-adherent cells would have a suppressor effect, HD-adherent cells were added in progressively increasing numbers to mononuclear cell suspensions depleted of glass wool-adherent cells. PHA responsiveness returned Mr.

show abstract

Section: Removal Of Glass Wool-adherent Cellsmentioning

confidence: 88%

Studies of Cell Subpopulations Mediating Mitogen Hyporesponsiveness in Patients with Hodgkin's Disease

Sibbitt¹,

Bankhurst²,

Williams³

1978

J. Clin. Invest.

View full text Add to dashboard Cite

show abstract

“…Subsequent to its initial description, numerous claims surrounding transfer factor emerged, including enhanced wound healing [8], improved leukocyte chemotaxis [9], and antineoplastic activity [10][11][12]. Reports following the discovery of the maternal transfer of antibodies [13] asserted that dialyzed bovine colostrum activated similar pathways as leukocyte extracts but failed to clarify if these findings were attributable to the same mechanisms [14].…”

Section: Introductionmentioning

confidence: 99%

CD8+ T cells produce a dialyzable antigen-specific activator of dendritic cells

Myles

Zhao

Nardone

et al. 2016

Journal of Leukocyte Biology

View full text Add to dashboard Cite

Cellular lysates from PPD donors have been reported to transfer tuberculin reactivity to naïve recipients, but not diphtheria reactivity, and vice versa. A historically controversial topic, the terms "transfer factor" and "DLE" were used to characterize the reactivity-transferring properties of lysates. Intrigued by these reported phenomena, we found that the cellular extract derived from antigen-specific memory CD8 T cells induces IL-6 from antigen-matched APCs. This ultimately elicits IL-17 from bystander memory CD8 T cells. We have identified that dialyzable peptide sequences, S100a9, and the TCR β chain from CD8 T cells contribute to the molecular nature of this activity. We further show that extracts from antigen-targeted T cells enhance immunity to Staphylococcus aureus and Candida albicans These effects are sensitive to immunization protocols and extraction methodology in ways that may explain past discrepancies in the reproducibility of passive cellular immunity.

show abstract

“…63,64 Several groups of investigators have studied the use of TF in Hodgkin's disease, [65][66][67] but its specificity for any particular antigen was not determined. Transfer of cellular immunity was documented by skin test conversion and increased lymphocyte response to PHA, but clinical effect was not observed.…”

Section: Studies In Virus-associated Cancers Epstein-barr Virus-assocmentioning

confidence: 99%

Transfer Factor in Virus-Associated Malignancies: An Underestimated Weapon in Prevention and Treatment of Cancer

Levine

Pizza²,

Ajmera³

et al. 2011

Advances in Tumor Virology

View full text Add to dashboard Cite

Abstract:Transfer factor (TF) is a lymphocyte extract of low molecular weight capable of transferring antigen-specific information to T-lymphocytes. A number of reports have documented its efficacy in the control of acute viral infections, particularly those associated with herpes viruses. There have been also several reports of clinical trials utilizing Epstein-Barr Virus-specific TF in associated malignancies, particularly Burkitt's lymphoma and nasopharyngeal carcinoma. One of the more important advances in the field has been the ability to produce standardized TF in tissue culture or by animal immunization, allowing the opportunity to develop well-controlled clinical trials, and the possibility to replicate them in independent studies. This review discusses the studies that have provided the best information regarding the efficacy of TF in fighting viral infections and suggests areas where clinical trials could be most useful, such as the prevention of human papilloma virus induced cervical cancer and human T-cell lymphotropic virus induced adult T-cell leukemia/ lymphoma.

show abstract

Transfer Factor in Hodgkin's Disease

Cited by 16 publications

References 6 publications

Studies of Cell Subpopulations Mediating Mitogen Hyporesponsiveness in Patients with Hodgkin's Disease

Studies of Cell Subpopulations Mediating Mitogen Hyporesponsiveness in Patients with Hodgkin's Disease

CD8+ T cells produce a dialyzable antigen-specific activator of dendritic cells

Transfer Factor in Virus-Associated Malignancies: An Underestimated Weapon in Prevention and Treatment of Cancer

Contact Info

Product

Resources

About